Lysine analogues- chloromethyl ketones
Already in 1981 a medicinal chemist at Bayer in Wuppertal, Germany [Gerd Reinhardt, Ann. N.Y. Acad. Sci. 1981, 370, 836.] designed a series of direct acting Factor XIIIa blockers. According to the author the molecule combines the substrate amine architecture (Lysine co-substrate) with the chemical reactivity of the sulfhydryl reagent (active site cysteine attacking the chloromethyl ketone). The compound inhibits at least tissue transglutaminase as well.
Art. No.
Name
Quantity
Price
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering